Open dataset · Generic Drug Price Cliff · doi:10.5281/zenodo.24182324
Two years after
80%
Five years after
46%
Ten years after
22%
200 generic tablet and capsule products matched to a single-ingredient Orange Book group with a dated first brand and first generic approval from 2013 to 2022, each with its year-end acquisition cost indexed to its first observed year-end price at or after the first generic approval, and the curve across them by years since that approval.
NADAC is what retail pharmacies pay to acquire a drug, not a retail price. The first observed year-end price can already reflect generic entry. Matching is by name and form kind, not strength. About 2 percent of the products considered are eligible, so the curve describes a minority of drugs.
The files are hosted on Zenodo with the DOI. Each has a SHA-256 hash, so a downloaded copy can be checked against it.
| File | Size | SHA-256 (first 16) |
|---|---|---|
| README.md | 2 KB | bd918425c12c29c4 |
| curve.csv | 419 bytes | e42cbf3d103ba98b |
| product-paths.csv | 110 KB | b5e6004166c1cd88 |
| dropped-products.csv | 172 bytes | 53a625d4ab9eac73 |
| data.json | 2 KB | 9e80306821840d51 |
| control-result.json | 359 bytes | e443cd1ad7c06653 |
| PROTOCOL-GENERIC-CLIFF-2026-11-12.md | 5 KB | e59f5eeba2426530 |
| protocol.sha256 | 103 bytes | df2ae034d1886c93 |
| protocol.original.sha256 | 103 bytes | bf8aa14951161f2d |
| code.zip | 22 KB | a3e7fb2e244bd873 |
| SHA256SUMS.txt | 1019 bytes | |
The method was frozen before any figure was published, on 12 November 2026; its SHA-256 hash begins e59f5eeba2426530. A separate reader recomputed figures from the raw files: a random sample recomputed, 0 mismatches. Read how the Generic Price Cliff was checked, including what the check found and what it does not cover.
That the first generic caused a price fall; that any drug will follow the curve; anything about retail prices, copays or patient costs.
Amendment 1 (2026-11-12, before publication): the first matching let a single-ingredient capsule match a three-drug combination group; matching now requires a single-ingredient group and exactly one of tablet or capsule in the form. Control: 200 products and 14 curve years, 0 mismatches.
Couey, V. W. (2026). Generic Drug Price Cliff 2013-2026: How Acquisition Cost Moves After the First Generic Approval, 200 Drugs (Version 1.0) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.24182324
Cite all versions: doi:10.5281/zenodo.24182323. This version: doi:10.5281/zenodo.24182324.
CMS National Average Drug Acquisition Cost yearly datasets (data.medicaid.gov) and FDA Orange Book data files, read 2026-11-12. Compiled by Vincent Wesley Couey (ORCID 0009-0005-6869-308X). Tool: https://rxgrab.com/tools/generic-price-cliff
200 generic tablet and capsule products matched to a single-ingredient Orange Book group with a dated first brand and first generic approval from 2013 to 2022, each with its year-end acquisition cost indexed to its first observed year-end price at or after the first generic approval, and the curve across them by years since that approval.
Yes. The compilation is licensed CC BY 4.0: reuse it with credit, citing the DOI (10.5281/zenodo.24182324). The underlying records keep the terms of their public source.
The method was frozen and hashed before any figure was published (12 November 2026), and a separate reader recomputed figures from the raw files: a random sample recomputed, 0 mismatches. The full account is on the how-we-check page for the tool.
That the first generic caused a price fall; that any drug will follow the curve; anything about retail prices, copays or patient costs.
Compiled by Vincent Wesley Couey (ORCID 0009-0005-6869-308X).